A retrospective, case control study assessing the comparison in weight changes between three groups of parkinson disease include patients treated either with LCIG, or subthalamic nucleus deep brain stimulation (STN-DBS) or receiving standard of care treatment (SOC)
Latest Information Update: 27 Oct 2021
At a glance
- Drugs Levodopa/carbidopa (Primary) ; Antiparkinsonians
- Indications Parkinson's disease
- Focus Adverse reactions
- 27 Oct 2021 New trial record
- 01 Oct 2021 Results published in the Revue Neurologique